Yorba Linda, Ca (PRWEB) December 23, 2016
Parathyroid hormone (PTH) is an 84 amino acid that plays a key role in phosphocalcic metabolism. Its measurement is essential to diagnose and treat primary hyperparathyroidism and to evaluate chronic kidney disease-mineral and bone disorders (CKD-MBD). PTH determination is not an easy task, mainly because of the many similar fragments that circulate in our blood.
Because these fragments are recognized differently by the various assays, the values obtained are often very different between “intact” kits. Up to now, 3rd generation PTH assays have not demonstrated any clinical benefit over intact PTH assays. However, PTH standardization can be achieved only with 3rd generation and it will be impossible to standardize assays using the intact PTH kits, because of variable cross-reactivities to fragments.
It is important to carefully select the “normal” subjects to establish reference ranges that allow the proper interpretation of the patient’s PTH results. These “normals” should not have secondary hyperparathyroidism and should have eGFR, 25(OH)D, calcium and phosphorus levels within a normal range. Unfortunately, manufacturers have not judiciously selected their “normals”, leading to falsely elevated PTH reference ranges. Using correctly established PTH reference ranges will assist physicians in correctly classifying HD patients in the appropriate bone turnover category.
Participants of the webinar will better understand the importance of good reference range establishment for PTH and PTH standardization. They can also expect to learn how best to get up-to-date information regarding PTH stability.
Dr. Etienne Cavalier, professor of clinical chemistry at the University of Liege and Head of the Department of Clinical Chemistry at the CHU de Liege, will be the presenter for this webinar.
Cavalier earned both a Master of Sciences in pharmaceutical sciences and an Advanced Master in clinical biology from the University of Liege. He then went on to earn his PhD in Pharmaceutical and Biomedical Sciences from the same university. In his current role, Cavalier is the professor of clinical chemistry at the University of Liege and head of the Department of Clinical Chemistry at the CHU de Liege. His main research topics are linked with the phosphocalcic metabolism, renal function, frailty and sarcopenia.
LabRoots will host the free webinar on February 15, 2017, beginning at 9:00 a.m. PT, 12 p.m. ET. To find out more on this event, learn about continuing education credits or to register for free, click here.
Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist.”
LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.